Trials / Completed
CompletedNCT03576443
Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma
A Phase II Trial of Idelalisib in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Nordic Lymphoma Group · Network
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Based on the high response rate in heavily pretreated patients with indolent B-cell lymphomas, among which it is likely that many have undetected transformed disease, the investigators hypothesize that idelalisib may also be active in relapsed DLBCL, particularly of the GCB subtype. Possibly, the efficacy may be related to the presence of specific mutations within the B-cell receptor pathway.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idelalisib | Idelalisib 150 mg x 2 p o |
Timeline
- Start date
- 2017-07-07
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
- First posted
- 2018-07-03
- Last updated
- 2021-10-13
Locations
6 sites across 2 countries: Denmark, Sweden
Source: ClinicalTrials.gov record NCT03576443. Inclusion in this directory is not an endorsement.